Topic Highlight
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jun 7, 2015; 21(21): 6470-6478
Published online Jun 7, 2015. doi: 10.3748/wjg.v21.i21.6470
Table 1 Differences regarding survival, treatment, and molecular levels between right and left colon cancer.
RCCLCC
Survival
5-yr OS in 1990s56.3%59.7%P < 0.01
in 2000s67%71%P < 0.01
5-yr DFS in 201073%74%P > 0.05
in 201488.6%89.4%P > 0.05
Median OS (mo)18.2%29.4%P < 0.001
Dominant treatment - AdjuvantFOLFIRIFOLFOX
PalliativeAnti-EGFR therapyAnti-angiogenesis
Molecular levels
Carcinogenesis mechanismsMMR, KRAS, BRAF, miRNA-31CIN (p53), NRAS; miRNA-146a, 147b, 1288
Protein expressionsGNAS, NQO1, Telomerase, p-PDHANXA10, Topo I,
TS, EGFR
Relapse pathwaysCell cycle control genes, high WNT signalingStromal expression, low WNT signaling
Prognostic biomarkersCDX2, ITGA3NOX4